Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 28 May 2020

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.

Overweight, obese teens more likely to develop papillary thyroid cancer as adults

01 Apr 2020

Being overweight or obese in adolescence appears to increase the risk of papillary thyroid cancer (PTC) in adulthood, a recent study has shown.

The study included 1,549 PTC patients (mean age, 50.7±9.4 years; 80.6 percent female), from whom weight information at 18 years of age were obtained through an in-person interview with a structured questionnaire. Current weight measurements were also collected. Researchers also included 15,490 no-PTC controls (mean age, 50.8±9.1 years; 80.6 percent female) for comparison.

Having a body mass index (BMI) of at least 25.0 kg/m2 at age 18 years emerged as a significant risk factor of PTC in adulthood after controlling for potential confounders (odds ratio [OR], 4.31, 95 percent confidence interval [CI], 3.57–5.22). This was relative to BMI <23.0 kg/m2 in adolescence.

Stratified analyses according to sex showed a stronger effect for men (OR, 6.65, 95 percent CI, 4.76–9.27), though the influence of BMI on PTC risk remained significant in women, too (OR, 3.49, 95 percent CI, 2.74–4.43).

Similarly, analysis according to current BMI showed no potential effect modification. High BMI at 18 years of age was predictive of adulthood PTC in the subgroups of patients with current BMI 25 kg/m2 (OR, 8.21, 95 percent CI, 6.34–10.62) and <25.0 kg/m2 (OR, 2.21, 95 percent CI, 1.49–3.27). The difference in the magnitude of effect was statistically significant (p<0.01).

“The results of the present study provide additional evidence that public health concerns and policy intervention are needed for weight management in adolescence to decrease the PTC risk,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 28 May 2020

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.